Oncologic applications of diffusion-weighted MRI in the body

Journal of Magnetic Resonance Imaging

Volumn 35, Issue 2, 2012, Pages 257-279

  Bonekamp, Susanne ^a   Corona Villalobos, Celia P ^a   Kamel, Ihab R ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

biomarker; cancer; cancer detection; diffusion weighted MRI; treatment monitoring

Indexed keywords

DOCETAXEL; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; PROSTATE SPECIFIC ANTIGEN;

BILE DUCT CARCINOMA; BREAST CANCER; CANCER STAGING; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFUSION TENSOR IMAGING; DIFFUSION WEIGHTED IMAGING; ECHO PLANAR IMAGING; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; FATTY LIVER; FIBROADENOMA; FIBROSIS; GALLBLADDER CARCINOMA; HUMAN; IN VIVO STUDY; KIDNEY CANCER; KIDNEY CARCINOMA; LIVER CANCER; LIVER INJURY; LIVER PARENCHYMA; LIVER TRANSPLANTATION; LUNG CARCINOMA; LUNG COLLAPSE; LUNG NODULE; LYMPH NODE METASTASIS; MICROSCOPY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGICAL PROCEDURES; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS CYST; PANCREAS TUMOR; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATECTOMY; QUANTITATIVE ANALYSIS; RADIOFREQUENCY IDENTIFICATION; RECTUM TUMOR; REVIEW; TREATMENT RESPONSE; UTERINE CERVIX CANCER;

EID: 84856297045     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.22786     Document Type: Review

References (222)

1. Le Bihan D, Breton E, Lallemand D, Grenier P, Cabanis E, Laval-Jeantet M,. MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology 1986; 161: 401-407. (Pubitemid 17173295)
2. Stejskal EO, Tanner JE,. Spin diffusion measurements: spin echoes in the presence of a time-dependent field gradient. J Chem Phys 1965; 42: 288.
3. de Figueiredo EH, Borgonovi AF, Doring TM,. Basic concepts of MR imaging, diffusion MR imaging, and diffusion tensor imaging. Magn Reson Imaging Clin N Am 2011; 19: 1-22.
4. Huisman TA,. Diffusion-weighted imaging: basic concepts and application in cerebral stroke and head trauma. Eur Radiol 2003; 13: 2283-2297. (Pubitemid 37220363)
5. Pagani E, Bizzi A, Di Salle F, De Stefano N, Filippi M,. Basic concepts of advanced MRI techniques. Neurol Sci 2008; 29 (Suppl 3): 290-295.
6. Padhani AR, Liu G, Koh DM, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009; 11: 102-125.
7. Moteki T, Horikoshi H,. Evaluation of hepatic lesions and hepatic parenchyma using diffusion-weighted echo-planar MR with three values of gradient b-factor. J Magn Reson Imaging 2006; 24: 637-645. (Pubitemid 44320568)
8. Zech CJ, Herrmann KA, Dietrich O, Horger W, Reiser MF, Schoenberg SO,. Black-blood diffusion-weighted EPI acquisition of the liver with parallel imaging: comparison with a standard T2-weighted sequence for detection of focal liver lesions. Invest Radiol 2008; 43: 261-266. (Pubitemid 351416769)
9. Hussain SM, De Becker J, Hop WC, Dwarkasing S, Wielopolski PA,. Can a single-shot black-blood T2-weighted spin-echo echo-planar imaging sequence with sensitivity encoding replace the respiratory-triggered turbo spin-echo sequence for the liver? An optimization and feasibility study. J Magn Reson Imaging 2005; 21: 219-229. (Pubitemid 40280115)
10. Qayyum A,. Diffusion-weighted imaging in the abdomen and pelvis: concepts and applications. Radiographics 2009; 29: 1797-1810.
11. Parikh T, Drew SJ, Lee VS, et al. Focal liver lesion detection and characterization with diffusion-weighted MR imaging: comparison with standard breath-hold T2-weighted imaging. Radiology 2008; 246: 812-822.
12. Okada Y, Ohtomo K, Kiryu S, Sasaki Y,. Breath-hold T2-weighted MRI of hepatic tumors: value of echo planar imaging with diffusion-sensitizing gradient. J Comput Assist Tomogr 1998; 22: 364-371. (Pubitemid 28396727)
13. Low RN, Gurney J,. Diffusion-weighted MRI (DWI) in the oncology patient: value of breathhold DWI compared to unenhanced and gadolinium-enhanced MRI. J Magn Reson Imaging 2007; 25: 848-858. (Pubitemid 46516739)
14. Bruegel M, Gaa J, Waldt S, et al. Diagnosis of hepatic metastasis: comparison of respiration-triggered diffusion-weighted echo-planar MRI and five t2-weighted turbo spin-echo sequences. AJR Am J Roentgenol 2008; 191: 1421-1429.
15. Kim T, Murakami T, Takahashi S, Hori M, Tsuda K, Nakamura H,. Diffusion-weighted single-shot echoplanar MR imaging for liver disease. AJR Am J Roentgenol 1999; 173: 393-398. (Pubitemid 29347365)
16. Taouli B, Vilgrain V, Dumont E, Daire JL, Fan B, Menu Y,. Evaluation of liver diffusion isotropy and characterization of focal hepatic lesions with two single-shot echo-planar MR imaging sequences: prospective study in 66 patients. Radiology 2003; 226: 71-78. (Pubitemid 36163910)
17. Bruegel M, Holzapfel K, Gaa J, et al. Characterization of focal liver lesions by ADC measurements using a respiratory triggered diffusion-weighted single-shot echo-planar MR imaging technique. Eur Radiol 2008; 18: 477-485. (Pubitemid 351248179)
18. Holzapfel K, Bruegel M, Eiber M, et al. Characterization of small (â‰10 mm) focal liver lesions: value of respiratory-triggered echo-planar diffusion-weighted MR imaging. Eur J Radiol 2010; 76: 89-95.
19. Gourtsoyianni S, Papanikolaou N, Yarmenitis S, Maris T, Karantanas A, Gourtsoyiannis N,. Respiratory gated diffusion-weighted imaging of the liver: value of apparent diffusion coefficient measurements in the differentiation between most commonly encountered benign and malignant focal liver lesions. Eur Radiol 2008; 18: 486-492.
20. Coenegrachts K, Delanote J, Ter Beek L, et al. Improved focal liver lesion detection: comparison of single-shot diffusion-weighted echoplanar and single-shot T2 weighted turbo spin echo techniques. Br J Radiol 2007; 80: 524-531. (Pubitemid 47343080)
21. Namimoto T, Yamashita Y, Sumi S, Tang Y, Takahashi M,. Focal liver masses: characterization with diffusion-weighted echo-planar MR imaging. Radiology 1997: 204: 739-744. (Pubitemid 27369034)
22. Ichikawa T, Haradome H, Hachiya J, Nitatori T, Araki T,. Diffusion-weighted MR imaging with a single-shot echoplanar sequence: detection and characterization of focal hepatic lesions. AJR Am J Roentgenol 1998: 170: 397- 402.
23. Oner AY, Celik H, Oktar SO, Tali T,. Single breath-hold diffusion-weighted MRI of the liver with parallel imaging: initial experience. Clin Radiol 2006: 61: 959-965. (Pubitemid 44464117)
24. Koh DM, Scurr E, Collins DJ, et al. Colorectal hepatic metastases: quantitative measurements using single-shot echo-planar diffusion-weighted MR imaging. Eur Radiol 2006: 16: 1898-1905. (Pubitemid 44193174)
25. Sandrasegaran K, Akisik FM, Lin C, Tahir B, Rajan J, Aisen AM,. The value of diffusion-weighted imaging in characterizing focal liver masses. Acad Radiol 2009; 16: 1208-1214.
26. Koike N, Cho A, Nasu K, et al. Role of diffusion-weighted magnetic resonance imaging in the differential diagnosis of focal hepatic lesions. World J Gastroenterol 2009: 15: 5805-5812.
27. Nasu K, Kuroki Y, Tsukamoto T, Nakajima H, Mori K, Minami M,. Diffusion-weighted imaging of surgically resected hepatocellular carcinoma: imaging characteristics and relationship among signal intensity, apparent diffusion coefficient, and histopathologic grade. AJR Am J Roentgenol 2009; 193: 438-444.
28. Demir OI, Obuz F, Sagol O, Dicle O,. Contribution of diffusion-weighted MRI to the differential diagnosis of hepatic masses. Diagn Interv Radiol 2007: 13: 81-86. (Pubitemid 46881935)
29. Hardie AD, Naik M, Hecht EM, et al. Diagnosis of liver metastases: value of diffusion-weighted MRI compared with gadolinium-enhanced MRI. Eur Radiol 2010.
30. Erturk SM, Ichikawa T, Sano K, Motosugi U, Sou H, Araki T,. Diffusion-weighted magnetic resonance imaging for characterization of focal liver masses: impact of parallel imaging (SENSE) and b value. J Comput Assist Tomogr 2008; 32: 865-871.
31. Taouli B, Koh DM,. Diffusion-weighted MR imaging of the liver. Radiology 2010; 254: 47-66.
32. Sandrasegaran K, Akisik FM, Lin C, et al. Value of diffusion-weighted MRI for assessing liver fibrosis and cirrhosis. AJR Am J Roentgenol 2009; 193: 1556-1560.
33. Taouli B, Chouli M, Martin AJ, Qayyum A, Coakley FV, Vilgrain V,. Chronic hepatitis: role of diffusion-weighted imaging and diffusion tensor imaging for the diagnosis of liver fibrosis and inflammation. J Magn Reson Imaging 2008; 28: 89-95. (Pubitemid 351956470)
34. Bittencourt LK, Matos C, Coutinho AC Jr,. Diffusion-weighted magnetic resonance imaging in the upper abdomen: technical issues and clinical applications. Magn Reson Imaging Clin N Am 2011; 19: 111-131.
35. Bruix J, Llovet JM,. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35: 519-524. (Pubitemid 34183954)
36. Proye C,. Natural history of liver metastasis of gastroenteropancreatic neuroendocrine tumors: place for chemoembolization. World J Surg 2001; 25: 685-688. (Pubitemid 32531908)
37. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
38. Kamel IR, Liapi E, Reyes DK, Zahurak M, Bluemke DA, Geschwind JF,. Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology 2009; 250: 466-473.
39. Reyes DK, Vossen JA, Kamel IR, et al. Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. Cancer J 2009; 15: 526-532.
40. Buijs M, Vossen JA, Hong K, Georgiades CS, Geschwind JF, Kamel IR,. Chemoembolization of hepatic metastases from ocular melanoma: assessment of response with contrast-enhanced and diffusion-weighted MRI. AJR Am J Roentgenol 2008; 191: 285-289. (Pubitemid 351955216)
41. Vossen JA, Kamel IR, Buijs M, et al. Role of functional magnetic resonance imaging in assessing metastatic leiomyosarcoma response to chemoembolization. J Comput Assist Tomogr 2008; 32: 347-352.
42. Buijs M, Kamel IR, Vossen JA, Georgiades CS, Hong K, Geschwind JF,. Assessment of metastatic breast cancer response to chemoembolization with contrast agent enhanced and diffusion-weighted MR imaging. J Vasc Interv Radiol 2007; 18: 957-963. (Pubitemid 47126311)
43. Kamel IR, Reyes DK, Liapi E, Bluemke DA, Geschwind JF,. Functional MR imaging assessment of tumor response after 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2007; 18: 49-56. (Pubitemid 46616678)
44. Thoeny HC, De Keyzer F, Vandecaveye V, et al. Effect of vascular targeting agent in rat tumor model: dynamic contrast-enhanced versus diffusion-weighted MR imaging. Radiology 2005; 237: 492-499. (Pubitemid 41507886)
45. Mannelli L, Kim S, Hajdu CH, Babb JS, Clark TW, Taouli B,. Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver. AJR Am J Roentgenol 2009; 193: 1044-1052.
46. Goshima S, Kanematsu M, Kondo H, et al. Evaluating local hepatocellular carcinoma recurrence post-transcatheter arterial chemoembolization: is diffusion-weighted MRI reliable as an indicator? J Magn Reson Imaging 2008; 27: 834-839. (Pubitemid 351508099)
47. Yu JS, Kim JH, Chung JJ, Kim KW,. Added value of diffusion-weighted imaging in the MRI assessment of perilesional tumor recurrence after chemoembolization of hepatocellular carcinomas. J Magn Reson Imaging 2009; 30: 153-160.
48. Sugita R, Yamazaki T, Furuta A, Itoh K, Fujita N, Takahashi S,. High b-value diffusion-weighted MRI for detecting gallbladder carcinoma: preliminary study and results. Eur Radiol 2009; 19: 1794-1798.
49. Cui XY, Chen HW,. Role of diffusion-weighted magnetic resonance imaging in the diagnosis of extrahepatic cholangiocarcinoma. World J Gastroenterol 2010; 16: 3196-3201.
50. Yoshikawa T, Kawamitsu H, Mitchell DG, et al. ADC measurement of abdominal organs and lesions using parallel imaging technique. AJR Am J Roentgenol 2006; 187: 1521-1530. (Pubitemid 44788683)
51. Ichikawa T, Haradome H, Hachiya J, Nitatori T, Araki T,. Diffusion-weighted MR imaging with single-shot echo-planar imaging in the upper abdomen: preliminary clinical experience in 61 patients. Abdom Imaging 1999; 24: 456-461. (Pubitemid 29411497)
52. Yamada I, Aung W, Himeno Y, Nakagawa T, Shibuya H,. Diffusion coefficients in abdominal organs and hepatic lesions: evaluation with intravoxel incoherent motion echo-planar MR imaging. Radiology 1999; 210: 617-623. (Pubitemid 29124018)
53. Dale BM, Braithwaite AC, Boll DT, Merkle EM,. Field strength and diffusion encoding technique affect the apparent diffusion coefficient measurements in diffusion-weighted imaging of the abdomen. Invest Radiol 2010; 45: 104-108.
54. Matsuki M, Inada Y, Nakai G, et al. Diffusion-weighed MR imaging of pancreatic carcinoma. Abdom Imaging 2007; 32: 481-483. (Pubitemid 47383877)
55. Irie H, Honda H, Kuroiwa T, et al. Measurement of the apparent diffusion coefficient in intraductal mucin-producing tumor of the pancreas by diffusion-weighted echo-planar MR imaging. Abdom Imaging 2002; 27: 82-87. (Pubitemid 36459870)
56. Fattahi R, Balci NC, Perman WH, et al. Pancreatic diffusion-weighted imaging (DWI): comparison between mass-forming focal pancreatitis (FP), pancreatic cancer (PC), and normal pancreas. J Magn Reson Imaging 2009; 29: 350-356.
57. Lee SS, Byun JH, Park BJ, et al. Quantitative analysis of diffusion-weighted magnetic resonance imaging of the pancreas: usefulness in characterizing solid pancreatic masses. J Magn Reson Imaging 2008; 28: 928-936.
58. Muraoka N, Uematsu H, Kimura H, et al. Apparent diffusion coefficient in pancreatic cancer: characterization and histopathological correlations. J Magn Reson Imaging 2008; 27: 1302-1308. (Pubitemid 351770681)
59. Nishie A, Obuchi M, Howe J, Dahmoush L, Stolpen A,. Small islet cell tumour in the pancreas: diagnostic value of diffusion-weighted MRI. J Med Imaging Radiat Oncol 2008; 52: 374-375.
60. Bakir B, Salmaslioglu A, Poyanli A, Rozanes I, Acunas B,. Diffusion weighted MR imaging of pancreatic islet cell tumors. Eur J Radiol 2010; 74: 214-220.
61. Inan N, Arslan A, Akansel G, Anik Y, Demirci A,. Diffusion-weighted imaging in the differential diagnosis of cystic lesions of the pancreas. AJR Am J Roentgenol 2008; 191: 1115-1121.
62. Li D, Xie K, Wolff R, Abbruzzese JL,. Pancreatic cancer. Lancet 2004; 363: 1049-1057. (Pubitemid 38410779)
63. Niwa T, Ueno M, Ohkawa S, et al. Advanced pancreatic cancer: the use of the apparent diffusion coefficient to predict response to chemotherapy. Br J Radiol 2009; 82: 28-34.
64. Murphy GP, Tjoa BA, Simmons SJ, et al. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 1999; 38: 73-78. (Pubitemid 29011020)
65. Petronis JD, Regan F, Lin K,. Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer. Clin Nucl Med 1998; 23: 672-677. (Pubitemid 28487326)
66. Ertan G, Tekes A, Mitchell S, Keefer J, Huisman TA,. Pediatric littoral cell angioma of the spleen: multimodality imaging including diffusion-weighted imaging. Pediatr Radiol 2009: 39: 1105-1109.
67. Wu M, Lin Y, Shieh C, et al. Measuring anisotropic diffusion in kidney using MRI. Acad Radiol 2011: 18: 1168-1174.
68. Thoeny HC, De Keyzer F, Oyen RH, Peeters RR,. Diffusion-weighted MR imaging of kidneys in healthy volunteers and patients with parenchymal diseases: initial experience. Radiology 2005: 235: 911-917. (Pubitemid 40695889)
69. Squillaci E, Manenti G, Cova M, et al. Correlation of diffusion-weighted MR imaging with cellularity of renal tumours. Anticancer Res 2004: 24: 4175-4179. (Pubitemid 40468724)
70. Zhang J, Tehrani YM, Wang L, Ishill NM, Schwartz LH, Hricak H,. Renal masses: characterization with diffusion-weighted MR imaging - a preliminary experience. Radiology 2008: 247: 458-464.
71. Cova M, Squillaci E, Stacul F, et al. Diffusion-weighted MRI in the evaluation of renal lesions: preliminary results. Br J Radiol 2004: 77: 851-857. (Pubitemid 39504641)
72. Wang H, Cheng L, Zhang X, et al. Renal cell carcinoma: diffusion-weighted MR imaging for subtype differentiation at 3.0 T. Radiology 2010: 257: 135-143.
73. Taouli B, Thakur RK, Mannelli L, et al. Renal lesions: characterization with diffusion-weighted imaging versus contrast-enhanced MR imaging. Radiology 2009; 251: 398-407.
74. Kilickesmez O, Inci E, Atilla S, et al. Diffusion-weighted imaging of the renal and adrenal lesions. J Comput Assist Tomogr 2009: 33: 828- 833.
75. Sandrasegaran K, Sundaram CP, Ramaswamy R, et al. Usefulness of diffusion-weighted imaging in the evaluation of renal masses. AJR Am J Roentgenol 2010; 194: 438-445.
76. Kim S, Jain M, Harris AB, et al. T1 hyperintense renal lesions: characterization with diffusion-weighted MR imaging versus contrast-enhanced MR imaging. Radiology 2009; 251: 796-807.
77. Merkle EM, Nour SG, Lewin JS,. MR imaging follow-up after percutaneous radiofrequency ablation of renal cell carcinoma: findings in 18 patients during first 6 months. Radiology 2005: 35: 1065-1071. (Pubitemid 40695910)
78. Tsushima Y, Takahashi-Taketomi A, Endo K,. Diagnostic utility of diffusion-weighted MR imaging and apparent diffusion coefficient value for the diagnosis of adrenal tumors. J Magn Reson Imaging 2009; 29: 112-117.
79. Miller FH, Wang Y, McCarthy RJ, et al. Utility of diffusion-weighted MRI in characterization of adrenal lesions. AJR Am J Roentgenol 2010; 194: W179-W185.
80. Djavan B, Moul JW, Zlotta A, Remzi M, Ravery V,. PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium. Eur Urol 2003; 43: 12-27. (Pubitemid 36134310)
81. Rao SX, Zeng MS, Chen CZ, et al. The value of diffusion-weighted imaging in combination with T2-weighted imaging for rectal cancer detection. Eur J Radiol 2008; 65: 299-303.
82. Ichikawa T, Erturk SM, Motosugi U, et al. High-B-value diffusion-weighted MRI in colorectal cancer. AJR Am J Roentgenol 2006; 187: 181-184. (Pubitemid 46100166)
83. Nasu K, Kuroki Y, Kuroki S, Murakami K, Nawano S, Moriyama N,. Diffusion-weighted single shot echo planar imaging of colorectal cancer using a sensitivity-encoding technique. Jpn J Clin Oncol 2004; 34: 620-626. (Pubitemid 40662718)
84. Kilickesmez O, Atilla S, Soylu A, et al. Diffusion-weighted imaging of the rectosigmoid colon: preliminary findings. J Comput Assist Tomogr 2009; 33: 863-866.
85. Soyer P, Lagadec M, Sirol M, et al. Free-breathing diffusion-weighted single-shot echo-planar MR imaging using parallel imaging (GRAPPA 2) and high b value for the detection of primary rectal adenocarcinoma. Cancer Imaging 2010; 10: 32-39.
86. DeVries AF, Kremser C, Hein PA, et al. Tumor microcirculation and diffusion predict therapy outcome for primary rectal carcinoma. Int J Radiat Oncol Biol Phys 2003; 56: 958-965. (Pubitemid 36794026)
87. Dzik-Jurasz A, Domenig C, George M, et al. Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet 2002; 360: 307-308. (Pubitemid 34874724)
88. Sun YS, Zhang XP, Tang L, et al. Locally advanced rectal carcinoma treated with preoperative chemotherapy and radiation therapy: preliminary analysis of diffusion-weighted MR imaging for early detection of tumor histopathologic downstaging. Radiology 2010; 254: 170-178.
89. Sakurada A, Takahara T, Kwee TC, et al. Diagnostic performance of diffusion-weighted magnetic resonance imaging in esophageal cancer. Eur Radiol 2009; 19: 1461-1469.
90. Shinya S, Sasaki T, Nakagawa Y, Guiquing Z, Yamamoto F, Yamashita Y,. The usefulness of diffusion-weighted imaging (DWI) for the detection of gastric cancer. Hepatogastroenterology 2007; 54: 1378-1381. (Pubitemid 47203430)
91. Low RN, Sebrechts CP, Barone RM, Muller W,. Diffusion-weighted MRI of peritoneal tumors: comparison with conventional MRI and surgical and histopathologic findings-a feasibility study. AJR Am J Roentgenol 2009; 193: 461-470.
92. Fujii S, Matsusue E, Kanasaki Y, et al. Detection of peritoneal dissemination in gynecological malignancy: evaluation by diffusion-weighted MR imaging. Eur Radiol 2008; 18: 18-23. (Pubitemid 351217273)
93. Thomassin-Naggara I, Darai E, Cuenod CA, et al. Contribution of diffusion-weighted MR imaging for predicting benignity of complex adnexal masses. Eur Radiol 2009; 19: 1544-1552.
94. Bozkurt M, Doganay S, Kantarci M, et al. Comparison of peritoneal tumor imaging using conventional MR imaging and diffusion-weighted MR imaging with different b values. Eur J Radiol 2010 [Epub ahead of print].
95. Guo Y, Cai YQ, Cai ZL, et al. Differentiation of clinically benign and malignant breast lesions using diffusion-weighted imaging. J Magn Reson Imaging 2002; 16: 172-178. (Pubitemid 34810055)
96. Rubesova E, Grell AS, De Maertelaer V, Metens T, Chao SL, Lemort M,. Quantitative diffusion imaging in breast cancer: a clinical prospective study. J Magn Reson Imaging 2006; 24: 319-324. (Pubitemid 44188557)
97. Woodhams R, Matsunaga K, Kan S, et al. ADC mapping of benign and malignant breast tumors. Magn Reson Med Sci 2005; 4: 35-42.
98. Partridge SC, Demartini WB, Kurland BF, Eby PR, White SW, Lehman CD,. Differential diagnosis of mammographically and clinically occult breast lesions on diffusion-weighted MRI. J Magn Reson Imaging 2010; 31: 562-570.
99. Kul S, Cansu A, Alhan E, Dinc H, Gunes G, Reis A,. Contribution of diffusion-weighted imaging to dynamic contrast-enhanced MRI in the characterization of breast tumors. AJR Am J Roentgenol 2011; 196: 210-217.
100. Ei Khouli RH, Jacobs MA, Mezban SD, et al. Diffusion-weighted imaging improves the diagnostic accuracy of conventional 3.0-T breast MR imaging. Radiology 2010; 256: 64-73.
101. Englander SA, Ulug AM, Brem R, Glickson JD, van Zijl PC,. Diffusion imaging of human breast. NMR Biomed 1997; 10: 348-352. (Pubitemid 28028424)
102. Partridge SC, DeMartini WB, Kurland BF, Eby PR, White SW, Lehman CD,. Quantitative diffusion-weighted imaging as an adjunct to conventional breast MRI for improved positive predictive value. AJR Am J Roentgenol 2009; 193: 1716-1722.
103. Yabuuchi H, Matsuo Y, Okafuji T, et al. Enhanced mass on contrast-enhanced breast MR imaging: lesion characterization using combination of dynamic contrast-enhanced and diffusion-weighted MR images. J Magn Reson Imaging 2008; 28: 1157-1165.
104. Costantini M, Belli P, Rinaldi P, et al. Diffusion-weighted imaging in breast cancer: relationship between apparent diffusion coefficient and tumour aggressiveness. Clin Radiol 2010; 65: 1005-1012.
105. Kuroki Y, Nasu K,. Advances in breast MRI: diffusion-weighted imaging of the breast. Breast Cancer 2008; 15: 212-217.
106. Woodhams R, Kakita S, Hata H, et al. Diffusion-weighted imaging of mucinous carcinoma of the breast: evaluation of apparent diffusion coefficient and signal intensity in correlation with histologic findings. AJR Am J Roentgenol 2009; 193: 260-266.
107. Woodhams R, Matsunaga K, Iwabuchi K, et al. Diffusion-weighted imaging of malignant breast tumors: the usefulness of apparent diffusion coefficient (ADC) value and ADC map for the detection of malignant breast tumors and evaluation of cancer extension. J Comput Assist Tomogr 2005; 29: 644-649. (Pubitemid 41395779)
108. Yili Z, Xiaoyan H, Hongwen D, et al. The value of diffusion-weighted imaging in assessing the ADC changes of tissues adjacent to breast carcinoma. BMC Cancer 2009; 9: 18.
109. Kim SH, Cha ES, Kim HS, et al. Diffusion-weighted imaging of breast cancer: correlation of the apparent diffusion coefficient value with prognostic factors. J Magn Reson Imaging 2009; 30: 615-620.
110. Nilsen L, Fangberget A, Geier O, Olsen DR, Seierstad T,. Diffusion-weighted magnetic resonance imaging for pretreatment prediction and monitoring of treatment response of patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. Acta Oncol 2010; 49: 354-360.
111. Woodhams R, Kakita S, Hata H, et al. Identification of residual breast carcinoma following neoadjuvant chemotherapy: diffusion-weighted imaging-comparison with contrast-enhanced MR imaging and pathologic findings. Radiology 2010; 254: 357-366.
112. Park SH, Moon WK, Cho N, et al. Diffusion-weighted MR imaging: pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer. Radiology 2010; 257: 56-63.
113. Pickles MD, Gibbs P, Lowry M, Turnbull LW,. Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging 2006; 24: 843-847. (Pubitemid 44205378)
114. Li XR, Cheng LQ, Liu M, et al. DW-MRI ADC values can predict treatment response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. Med Oncol 2011 [Epub ahead of print].
115. Fangberget A, Nilsen LB, Hole KH, et al. Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging. Eur Radiol 2010; 21: 1188-1199.
116. Tozaki M, Oyama Y, Fukuma E,. Preliminary study of early response to neoadjuvant chemotherapy after the first cycle in breast cancer: comparison of 1H magnetic resonance spectroscopy with diffusion magnetic resonance imaging. Jpn J Radiol 2010; 28: 101-109.
117. Sharma U, Danishad KK, Seenu V, Jagannathan NR,. Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. NMR Biomed 2009; 22: 104-113.
118. Matoba M, Tonami H, Kondou T, et al. Lung carcinoma: diffusion-weighted mr imaging-preliminary evaluation with apparent diffusion coefficient. Radiology 2007; 243: 570-577. (Pubitemid 46649714)
119. Uto T, Takehara Y, Nakamura Y, et al. Higher sensitivity and specificity for diffusion-weighted imaging of malignant lung lesions without apparent diffusion coefficient quantification. Radiology 2009; 252: 247-254.
120. Qi LP, Zhang XP, Tang L, Li J, Sun YS, Zhu GY,. Using diffusion-weighted MR imaging for tumor detection in the collapsed lung: a preliminary study. Eur Radiol 2009; 19: 333-341.
121. Kanauchi N, Oizumi H, Honma T, et al. Role of diffusion-weighted magnetic resonance imaging for predicting of tumor invasiveness for clinical stage IA non-small cell lung cancer. Eur J Cardiothorac Surg 2009; 35: 706-710; discussion 710-711.
122. Karabulut N,. Accuracy of diffusion-weighted MR imaging for differentiation of pulmonary lesions. Radiology 2009; 253: 899; author reply899- 900.
123. Khalil A, Thomassin-Naggara I, Gounant V, Nedelcu N, Marsault C, Carette MF,. [Perfusion and diffusion-weighted MR imaging in the early staging and the follow-up of patients with lung cancer]. Rev Pneumol Clin 2009; 65: 40-48.
124. Ohba Y, Nomori H, Mori T, et al. Is diffusion-weighted magnetic resonance imaging superior to positron emission tomography with fludeoxyglucose F 18 in imaging non-small cell lung cancer? J Thorac Cardiovasc Surg 2009; 138: 439-445.
125. Tanaka R, Horikoshi H, Nakazato Y, et al. Magnetic resonance imaging in peripheral lung adenocarcinoma: correlation with histopathologic features. J Thorac Imaging 2009; 24: 4-9.
126. Nomori H, Mori T, Ikeda K, et al. Diffusion-weighted magnetic resonance imaging can be used in place of positron emission tomography for N staging of non-small cell lung cancer with fewer false-positive results. J Thorac Cardiovasc Surg 2008; 135: 816-822. (Pubitemid 351417933)
127. Ohno Y, Koyama H, Onishi Y, et al. Non-small cell lung cancer: whole-body MR examination for M-stage assessment-utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT. Radiology 2008; 248: 643-654.
128. Satoh S, Kitazume Y, Ohdama S, Kimula Y, Taura S, Endo Y,. Can malignant and benign pulmonary nodules be differentiated with diffusion-weighted MRI? AJR Am J Roentgenol 2008; 191: 464-470.
129. Liu H, Liu Y, Yu T, Ye N,. Usefulness of diffusion-weighted MR imaging in the evaluation of pulmonary lesions. Eur Radiol 2010; 20: 807-815.
130. Mori T, Nomori H, Ikeda K, et al. Diffusion-weighted magnetic resonance imaging for diagnosing malignant pulmonary nodules/masses: comparison with positron emission tomography. J Thorac Oncol 2008; 3: 358-364. (Pubitemid 351489475)
131. Hasegawa I, Boiselle PM, Kuwabara K, Sawafuji M, Sugiura H,. Mediastinal lymph nodes in patients with non-small cell lung cancer: preliminary experience with diffusion-weighted MR imaging. J Thorac Imaging 2008; 23: 157-161.
132. Kosucu P, Tekinbas C, Erol M, et al. Mediastinal lymph nodes: assessment with diffusion-weighted MR imaging. J Magn Reson Imaging 2009; 30: 292-297.
133. Nakayama J, Miyasaka K, Omatsu T, et al. Metastases in mediastinal and hilar lymph nodes in patients with non-small cell lung cancer: quantitative assessment with diffusion-weighted magnetic resonance imaging and apparent diffusion coefficient. J Comput Assist Tomogr 2010; 34: 1-8.
134. Chan VO, McDermott S, Malone DE, Dodd JD,. Percutaneous radiofrequency ablation of lung tumors: evaluation of the literature using evidence-based techniques. J Thorac Imaging 2011; 26: 18-26.
135. Okuma T, Matsuoka T, Yamamoto A, Hamamoto S, Nakamura K, Inoue Y,. Assessment of early treatment response after CT-guided radiofrequency ablation of unresectable lung tumours by diffusion-weighted MRI: a pilot study. Br J Radiol 2009; 82: 989-994.
136. Tamai K, Koyama T, Saga T, et al. Diffusion-weighted MR imaging of uterine endometrial cancer. J Magn Reson Imaging 2007; 26: 682-687. (Pubitemid 350194592)
137. Fujii S, Matsusue E, Kigawa J, et al. Diagnostic accuracy of the apparent diffusion coefficient in differentiating benign from malignant uterine endometrial cavity lesions: initial results. Eur Radiol 2008; 18: 384-389. (Pubitemid 351234060)
138. Kilickesmez O, Yirik G, Bayramoglu S, Cimilli T, Aydin S,. Non-breath-hold high b-value diffusion-weighted MRI with parallel imaging technique: apparent diffusion coefficient determination in normal abdominal organs. Diagn Interv Radiol 2008; 14: 83-87. (Pubitemid 352002996)
139. Inada Y, Matsuki M, Nakai G, et al. Body diffusion-weighted MR imaging of uterine endometrial cancer: is it helpful in the detection of cancer in nonenhanced MR imaging? Eur J Radiol 2009; 70: 122-127.
140. Shen SH, Chiou YY, Wang JH, et al. Diffusion-weighted single-shot echo-planar imaging with parallel technique in assessment of endometrial cancer. AJR Am J Roentgenol 2008; 190: 481-488.
141. Rechichi G, Galimberti S, Signorelli M, Perego P, Valsecchi MG, Sironi S,. Myometrial invasion in endometrial cancer: diagnostic performance of diffusion-weighted MR imaging at 1.5-T. Eur Radiol 2010; 20: 754-762.
142. Wang J, Yu T, Bai R, Sun H, Zhao X, Li Y,. The value of the apparent diffusion coefficient in differentiating stage IA endometrial carcinoma from normal endometrium and benign diseases of the endometrium: initial study at 3-T magnetic resonance scanner. J Comput Assist Tomogr 2010; 34: 332-337.
143. McVeigh PZ, Syed AM, Milosevic M, Fyles A, Haider MA,. Diffusion-weighted MRI in cervical cancer. Eur Radiol 2008; 18: 1058-1064.
144. Charles-Edwards E, Morgan V, Attygalle AD, et al. Endovaginal magnetic resonance imaging of stage 1A/1B cervical cancer with a T2- and diffusion-weighted magnetic resonance technique: effect of lesion size and previous cone biopsy on tumor detectability. Gynecol Oncol 2011; 120: 368-373.
145. Hoogendam JP, Klerkx WM, de Kort GA, et al. The influence of the b-value combination on apparent diffusion coefficient based differentiation between malignant and benign tissue in cervical cancer. J Magn Reson Imaging 2010; 32: 376-382.
146. Payne GS, Schmidt M, Morgan VA, et al. Evaluation of magnetic resonance diffusion and spectroscopy measurements as predictive biomarkers in stage 1 cervical cancer. Gynecol Oncol 2010; 116: 246-252.
147. Chen YB, Liao J, Xie R, Chen GL, Chen G,. Discrimination of metastatic from hyperplastic pelvic lymph nodes in patients with cervical cancer by diffusion-weighted magnetic resonance imaging. Abdom Imaging 2011; 36: 102-109.
148. Charles-Edwards EM, Messiou C, Morgan VA, et al. Diffusion-weighted imaging in cervical cancer with an endovaginal technique: potential value for improving tumor detection in stage Ia and Ib1 disease. Radiology 2008; 249: 541-550.
149. Naganawa S, Sato C, Kumada H, Ishigaki T, Miura S, Takizawa O,. Apparent diffusion coefficient in cervical cancer of the uterus: comparison with the normal uterine cervix. Eur Radiol 2005; 15: 71-78. (Pubitemid 40109773)
150. Choi EK, Kim JK, Choi HJ, et al. Node-by-node correlation between MR and PET/CT in patients with uterine cervical cancer: diffusion-weighted imaging versus size-based criteria on T2WI. Eur Radiol 2009; 19: 2024-2032.
151. Lin G, Ho KC, Wang JJ, et al. Detection of lymph node metastasis in cervical and uterine cancers by diffusion-weighted magnetic resonance imaging at 3T. J Magn Reson Imaging 2008; 28: 128-135. (Pubitemid 351956475)
152. Liu Y, Bai R, Sun H, Liu H, Wang D,. Diffusion-weighted magnetic resonance imaging of uterine cervical cancer. J Comput Assist Tomogr 2009; 33: 858-862.
153. Kim JK, Kim KA, Park BW, Kim N, Cho KS,. Feasibility of diffusion-weighted imaging in the differentiation of metastatic from nonmetastatic lymph nodes: early experience. J Magn Reson Imaging 2008; 28: 714-719.
154. Nakai G, Matsuki M, Inada Y, et al. Detection and evaluation of pelvic lymph nodes in patients with gynecologic malignancies using body diffusion-weighted magnetic resonance imaging. J Comput Assist Tomogr 2008; 32: 764-768.
155. Park SO, Kim JK, Kim KA, et al. Relative apparent diffusion coefficient: determination of reference site and validation of benefit for detecting metastatic lymph nodes in uterine cervical cancer. J Magn Reson Imaging 2009; 29: 383-390.
156. Xue HD, Li S, Sun F, et al. Clinical application of body diffusion weighted MR imaging in the diagnosis and preoperative N staging of cervical cancer. Chin Med Sci J 2008; 23: 133-137.
157. Moteki T, Ishizaka H,. Diffusion-weighted EPI of cystic ovarian lesions: evaluation of cystic contents using apparent diffusion coefficients. J Magn Reson Imaging 2000; 12: 1014-1019.
158. Kyriazi S, Collins DJ, Morgan VA, Giles SL, deSouza NM,. Diffusion-weighted imaging of peritoneal disease for noninvasive staging of advanced ovarian cancer. Radiographics 2010; 30: 1269-1285.
159. Takeuchi M, Matsuzaki K, Nishitani H,. Diffusion-weighted magnetic resonance imaging of ovarian tumors: differentiation of benign and malignant solid components of ovarian masses. J Comput Assist Tomogr 2010; 34: 173-176.
160. Fujii S, Kakite S, Nishihara K, et al. Diagnostic accuracy of diffusion-weighted imaging in differentiating benign from malignant ovarian lesions. J Magn Reson Imaging 2008; 28: 1149-1156.
161. Sarty GE, Kendall EJ, Loewy J, Dhir A, Olatunbosun OA, Pierson RA,. Magnetic resonance diffusion imaging of ovarian masses: a first experience with 12 cases. MAGMA 2004; 16: 182-193. (Pubitemid 38657624)
162. Moteki T, Ishizaka H,. Evaluation of cystic ovarian lesions using apparent diffusion coefficient calculated from reordered turboflash MR images. Magn Reson Imaging 1999; 17: 955-963. (Pubitemid 29420709)
163. Nakayama T, Yoshimitsu K, Irie H, et al. Diffusion-weighted echo-planar MR imaging and ADC mapping in the differential diagnosis of ovarian cystic masses: usefulness of detecting keratinoid substances in mature cystic teratomas. J Magn Reson Imaging 2005; 22: 271-278. (Pubitemid 41045442)
164. Katayama M, Masui T, Kobayashi S, et al. Diffusion-weighted echo planar imaging of ovarian tumors: is it useful to measure apparent diffusion coefficients? J Comput Assist Tomogr 2002; 26: 250-256. (Pubitemid 34233373)
165. Harry VN, Semple SI, Gilbert FJ, Parkin DE,. Diffusion-weighted magnetic resonance imaging in the early detection of response to chemoradiation in cervical cancer. Gynecol Oncol 2008; 111: 213-220.
166. Liu Y, Bai R, Sun H, Liu H, Zhao X, Li Y,. Diffusion-weighted imaging in predicting and monitoring the response of uterine cervical cancer to combined chemoradiation. Clin Radiol 2009; 64: 1067-1074.
167. Ries LAG, Melbert D, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975-2005. 2008.
168. Kim JH, Kim JK, Park BW, Kim N, Cho KS,. Apparent diffusion coefficient: prostate cancer versus noncancerous tissue according to anatomical region. J Magn Reson Imaging 2008; 28: 1173-1179.
169. Lim HK, Kim JK, Kim KA, Cho KS,. Prostate cancer: apparent diffusion coefficient map with T2-weighted images for detection-a multireader study. Radiology 2009; 250: 145-151.
170. Oto A, Kayhan A, Jiang Y, et al. Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology 2010; 257: 715-723.
171. Langer DL, van der Kwast TH, Evans AJ, et al. Intermixed normal tissue within prostate cancer: effect on MR imaging measurements of apparent diffusion coefficient and T2-sparse versus dense cancers. Radiology 2008; 249: 900-908.
172. Gibbs P, Tozer DJ, Liney GP, Turnbull LW,. Comparison of quantitative T2 mapping and diffusion-weighted imaging in the normal and pathologic prostate. Magn Reson Med 2001; 46: 1054-1058. (Pubitemid 33104291)
173. Chen M, Dang HD, Wang JY, et al. Prostate cancer detection: comparison of T2-weighted imaging, diffusion-weighted imaging, proton magnetic resonance spectroscopic imaging, and the three techniques combined. Acta Radiol 2008; 49: 602-610.
174. Kitajima K, Kaji Y, Fukabori Y, Yoshida K, Suganuma N, Sugimura K,. Prostate cancer detection with 3 T MRI: comparison of diffusion-weighted imaging and dynamic contrast-enhanced MRI in combination with T2-weighted imaging. J Magn Reson Imaging 2010; 31: 625-631.
175. Riches SF, Payne GS, Morgan VA, et al. MRI in the detection of prostate cancer: combined apparent diffusion coefficient, metabolite ratio, and vascular parameters. AJR Am J Roentgenol 2009; 193: 1583-1591.
176. Delongchamps NB, Rouanne M, Flam T, et al. Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2-weighted, dynamic contrast-enhanced and diffusion-weighted imaging. BJU Int 2011; 107: 1411-1418.
177. Katahira K, Takahara T, Kwee TC, et al. Ultra-high-b-value diffusion-weighted MR imaging for the detection of prostate cancer: evaluation in 201 cases with histopathological correlation. Eur Radiol 2011; 21: 188-196.
178. Gibbs P, Liney GP, Pickles MD, Zelhof B, Rodrigues G, Turnbull LW,. Correlation of ADC and T2 measurements with cell density in prostate cancer at 3.0 Tesla. Invest Radiol 2009; 44: 572-576.
179. Hambrock T, Somford DM, Huisman HJ, et al. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology 2011; 259: 453-461.
180. Turkbey B, Shah VP, Pang Y, et al. Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? Radiology 2011; 258: 488-495.
181. deSouza NM, Riches SF, Vanas NJ, et al. Diffusion-weighted magnetic resonance imaging: a potential non-invasive marker of tumour aggressiveness in localized prostate cancer. Clin Radiol 2008; 63: 774-782.
182. Woodfield CA, Tung GA, Grand DJ, Pezzullo JA, Machan JT, Renzulli JF Jr,. Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy. AJR Am J Roentgenol 2010; 194: W316-W322.
183. Morgan VA, Riches SF, Thomas K, et al. Diffusion-weighted magnetic resonance imaging for monitoring prostate cancer progression in patients managed by active surveillance. Br J Radiol 2011; 84: 31-37.
184. Heijmink SW, Futterer JJ, Hambrock T, et al. Prostate cancer: body-array versus endorectal coil MR imaging at 3 T-comparison of image quality, localization, and staging performance. Radiology 2007; 244: 184-195. (Pubitemid 46981973)
185. Lee SH, Park KK, Choi KH, et al. Is endorectal coil necessary for the staging of clinically localized prostate cancer? Comparison of non-endorectal versus endorectal MR imaging. World J Urol 2010; 28: 667-672.
186. Kim CK, Park BK, Lee HM,. Prediction of locally recurrent prostate cancer after radiation therapy: incremental value of 3T diffusion-weighted MRI. J Magn Reson Imaging 2009; 29: 391-397.
187. Arumainayagam N, Kumaar S, Ahmed HU, et al. Accuracy of multiparametric magnetic resonance imaging in detecting recurrent prostate cancer after radiotherapy. BJU Int 2010; 106: 991-997.
188. Nemoto K, Tateishi T, Ishidate T,. Changes in diffusion-weighted images for visualizing prostate cancer during antiandrogen therapy: preliminary results. Urol Int 2010; 85: 421-426.
189. Kim CK, Park BK, Lee HM, Kim SS, Kim E,. MRI techniques for prediction of local tumor progression after high-intensity focused ultrasonic ablation of prostate cancer. AJR Am J Roentgenol 2008; 190: 1180-1186. (Pubitemid 351684917)
190. Vogel-Claussen J, Gimi B, Artemov D, Bhujwalla ZM,. Diffusion-weighted and macromolecular contrast enhanced MRI of tumor response to antivascular therapy with ZD6126. Cancer Biol Ther 2007; 6: 1469-1475. (Pubitemid 351590360)
191. Jennings D, Hatton BN, Guo J, et al. Early response of prostate carcinoma xenografts to docetaxel chemotherapy monitored with diffusion MRI. Neoplasia 2002; 4: 255-262. (Pubitemid 34525257)
192. Matsuki M, Inada Y, Tatsugami F, Tanikake M, Narabayashi I, Katsuoka Y,. Diffusion-weighted MR imaging for urinary bladder carcinoma: initial results. Eur Radiol 2007; 17: 201-204. (Pubitemid 46063045)
193. Kilickesmez O, Cimilli T, Inci E, et al. Diffusion-weighted MRI of urinary bladder and prostate cancers. Diagn Interv Radiol 2009; 15: 104-110.
194. Abou-El-Ghar ME, El-Assmy A, Refaie HF, El-Diasty T,. Bladder cancer: diagnosis with diffusion-weighted MR imaging in patients with gross hematuria. Radiology 2009; 251: 415-421.
195. El-Assmy A, Abou-El-Ghar ME, Mosbah A, et al. Bladder tumour staging: comparison of diffusion- and T2-weighted MR imaging. Eur Radiol 2009; 19: 1575-1581.
196. Watanabe H, Kanematsu M, Kondo H, et al. Preoperative T staging of urinary bladder cancer: does diffusion-weighted MRI have supplementary value? AJR Am J Roentgenol 2009; 192: 1361-1366.
197. Takeuchi M, Sasaki S, Ito M, et al. Urinary bladder cancer: diffusion-weighted MR imaging-accuracy for diagnosing T stage and estimating histologic grade. Radiology 2009; 251: 112-121.
198. Yoshida S, Koga F, Kawakami S, et al. Initial experience of diffusion-weighted magnetic resonance imaging to assess therapeutic response to induction chemoradiotherapy against muscle-invasive bladder cancer. Urology 2010; 75: 387-391.
199. Chen W, Jian W, Li HT, et al. Whole-body diffusion-weighted imaging vs. FDG-PET for the detection of non-small-cell lung cancer. How do they measure up? Magn Reson Imaging 2010; 28: 613-620.
200. Sumi M, Van Cauteren M, Nakamura T,. MR microimaging of benign and malignant nodes in the neck. AJR Am J Roentgenol 2006; 186: 749-757. (Pubitemid 46100259)
201. Dirix P, Vandecaveye V, De Keyzer F, et al. Diffusion-weighted MRI for nodal staging of head and neck squamous cell carcinoma: impact on radiotherapy planning. Int J Radiat Oncol Biol Phys 2010; 76: 761-766.
202. Ono K, Ochiai R, Yoshida T, et al. Comparison of diffusion-weighted MRI and 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for detecting primary colorectal cancer and regional lymph node metastases. J Magn Reson Imaging 2009; 29: 336-340.
203. Holzapfel K, Duetsch S, Fauser C, Eiber M, Rummeny EJ, Gaa J,. Value of diffusion-weighted MR imaging in the differentiation between benign and malignant cervical lymph nodes. Eur J Radiol 2009; 72: 381-387.
204. de Bondt RB, Hoeberigs MC, Nelemans PJ, et al. Diagnostic accuracy and additional value of diffusion-weighted imaging for discrimination of malignant cervical lymph nodes in head and neck squamous cell carcinoma. Neuroradiology 2009; 51: 183-192.
205. Fukunari F, Okamura K, Zeze R, Kagawa T, Hashimoto K, Yuasa K,. Cervical lymph nodes with or without metastases from oral squamous carcinoma: a correlation of MRI findings and histopathologic architecture. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 109: 890-899.
206. Roy C, Bierry G, Matau A, Bazille G, Pasquali R,. Value of diffusion-weighted imaging to detect small malignant pelvic lymph nodes at 3 T. Eur Radiol 2010; 20: 1803-1811.
207. Eiber M, Beer AJ, Holzapfel K, et al. Preliminary results for characterization of pelvic lymph nodes in patients with prostate cancer by diffusion-weighted MR-imaging. Invest Radiol 2010; 45: 15-23.
208. Kwee TC, Takahara T, Luijten PR, Nievelstein RA,. ADC measurements of lymph nodes: inter- and intra-observer reproducibility study and an overview of the literature. Eur J Radiol 2010; 75: 215-220.
209. Goudarzi B, Kishimoto R, Komatsu S, et al. Detection of bone metastases using diffusion weighted magnetic resonance imaging: comparison with (11)C-methionine PET and bone scintigraphy. Magn Reson Imaging 2010; 28: 372-379.
210. Gutzeit A, Doert A, Froehlich JM, et al. Comparison of diffusion-weighted whole body MRI and skeletal scintigraphy for the detection of bone metastases in patients with prostate or breast carcinoma. Skeletal Radiol 2010; 39: 333-343.
211. Reischauer C, Froehlich JM, Koh DM, et al. Bone metastases from prostate cancer: assessing treatment response by using diffusion-weighted imaging and functional diffusion maps-initial observations. Radiology 2010; 257: 523-531.
212. Gutzeit A, Doert A, Froehlich JM, et al. Comparison of diffusion-weighted whole body MRI and skeletal scintigraphy for the detection of bone metastases in patients with prostate or breast carcinoma. Skeletal Radiol 2010; 39: 333-343.
213. Li S, Xue HD, Sun F, Jin ZY,. Feasibility and clinical value of whole body diffusion weighted magnetic resonance imaging in detection of bone metastases. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2009; 31: 192-199.
214. Takenaka D, Ohno Y, Matsumoto K, et al. Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy. J Magn Reson Imaging 2009; 30: 298-308.
215. Barcelo J, Vilanova JC, Riera E, et al. [Diffusion-weighted whole-body MRI (virtual PET) in screening for osseous metastases]. Radiologia 2007; 49: 407-415. (Pubitemid 350131823)
216. Kwee TC, Fijnheer R, Ludwig I, et al. Whole-body magnetic resonance imaging, including diffusion-weighted imaging, for diagnosing bone marrow involvement in malignant lymphoma. Br J Haematol 2010; 149: 628-630.
217. Heusner TA, Kuemmel S, Koeninger A, et al. Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging. Eur J Nucl Med Mol Imaging 2010; 37: 1077-1086.
218. Kwee TC, Takahara T, Vermoolen MA, Bierings MB, Mali WP, Nievelstein RA,. Whole-body diffusion-weighted imaging for staging malignant lymphoma in children. Pediatr Radiol 2010; 40: 1592-602; quiz 1720-1721.
219. Lin C, Luciani A, Itti E, et al. Whole-body diffusion-weighted magnetic resonance imaging with apparent diffusion coefficient mapping for staging patients with diffuse large B-cell lymphoma. Eur Radiol 2010; 20: 2027-2038.
220. Luciani A, Lin C, Beaussart P, Zerbib P, Haioun C, Rahmouni A,. [Whole body functional MR imaging: hemato-oncologic applications]. J Radiol 2010; 91: 375-380.
221. Kwee TC, van Ufford HM, Beek FJ, et al. Whole-body MRI, including diffusion-weighted imaging, for the initial staging of malignant lymphoma: comparison to computed tomography. Invest Radiol 2009; 44: 683-690.
222. Li S, Xue HD, Li J, et al. Application of whole body diffusion weighted MR imaging for diagnosis and staging of malignant lymphoma. Chin Med Sci J 2008; 23: 138-144.